// App-Quantinova.ai

168 : Treatment patterns after abiraterone acetate in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of COU-AA-302.

Researchers

Presenter

  • Thomas W. Flaig

Principal Investigators

  • Matthew R. Smith

  • Fred Saad

  • Dana E. Rathkopf

  • Peter F.A. Mulders

  • Eric Jay Small

  • Neal D. Shore

  • Karim Fizazi

  • Peter De Porre

  • Thian Kheoh

  • Jinhui Li

  • Mary Beth Todd

  • Thomas W. Griffin

  • Charles J. Ryan

  • Johann S. De Bono

Medical Centers

  • University of Colorado Cancer Center, Aurora, CO

  • Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA

  • University of Montreal, Montreal, QC, Canada

  • Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY

  • Radboud University Medical Center, Njmegen, Netherlands

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • Janssen Research & Development, Beerse, Belgium

  • Janssen Research & Development, San Diego, CA

  • Johnson & Johnson Medical China, Shanghai, China

  • Janssen Global Services, Raritan, NJ

  • Janssen Research & Development, Los Angeles, CA

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Locations

  • United States

  • Canada

  • Netherlands

  • France

  • Belgium

  • China

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT00887198

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved